All articles tagged: Hematology-Oncology

In a disease with dismal outcomes, KRAS inhibitors may offer hope for treating pancreatic cancer. But with preliminary data, experts remain cautiously optimistic.

A generic second-generation TKI is needed to help improve treatment-free remission rates.

Post-radiation dental extractions posed an elevated risk for exposed bone and osteoradionecrosis in patients with head and neck cancer.

Researchers analyzed whole genome sequencing data from 10,866 women in the WHI to explore possible associations between CHIP, mCA, and solid tumors.

Glimcher will be replaced by current medical oncology chief Benjamin Levine Ebert, MD, PhD, on October 1.

Researchers compared outcomes for patients randomized to receive androgen receptor pathway inhibitors, taxanes, or a physician's choice.

Patients with recurrent or metastatic head and neck squamous cell carcinoma can discontinue immune checkpoint inhibitors at 1 or 2 years without negatively impacting survival, a study suggests.

A study found that a range of factors, including younger age, lower income, advanced cancer stages, and higher social vulnerability, contributed to the financial strain.

Olanzapine improved complete response rates and quality of life in patients with solid tumors at moderate risk for chemotherapy-induced nausea and vomiting, new research shows.

GISTs have increased significantly over the past two decades, with Black patients experiencing higher mortality rates from esophageal and gastric GISTs.

A secondary analysis of the EVEREST trial found that adjuvant everolimus did not provide a recurrence-free or overall survival benefit in patients with localized non–clear cell RCC.

Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set...

A global study predicted an increase in cancer cases and deaths among men, with significant disparities based on age and the economic status of countries.

A new study evaluating long-term survival in clinical practice found that most patients who achieved a complete response on first-line immune checkpoint inhibitors lived beyond 3 years.

Researchers measured loneliness using an 11-item abbreviated version of the UCLA Loneliness Scale in a cohort of patients from the 2008-2018 Health and Retirement Study.

How a college friend's grim final days changed El-Jawahri's life and career path.

This nationwide cohort study based in Denmark may be the first to demonstrate that spouses of patients with cancer have a higher risk for suicide attempts and deaths.

Investigators analyzed data from men with prostate cancer who had MRI within 6 months before or after their initial biopsy.

Real-world meta-analysis found benefit of third- and later-line liposomal irinotecan is not affected by prior conventional irinotecan.

Individuals with small, peripheral, node-negative NSCLC and visceral pleural invasion had higher recurrence rates than those without pleural involvement, but similar overall survival rates.

Up to 57% of female cancer survivors report significant sexual dysfunction in adulthood.

Researchers analyzed data from patients with early breast cancer who were randomized to receive high-dose or no radiotherapy.

Researchers compared the efficacy and safety of belzutifan vs everolimus in patients with advanced clear cell renal cell carcinoma.

The agency sent Regeneron a complete response letter based on findings from a preapproval inspection, which will delay the potential approval of its myeloma drug, linvoseltamab.

Roughly 40% of cancer cases and 44% of cancer deaths in the United States in 2019 were attributable to potentially modifiable risk factors, a recent analysis found.

Weber was a pioneer in cancer immunotherapy and melanoma research and a valued Medscape Oncology contributor.

An analysis of patients with lung metastases from colorectal cancer showed that definitive surgery and ablative radiation offered similar 5-year overall survival benefits.

The combination is now approved in the frontline for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

Researchers warn that the test makers should not influence the design of the studies that evaluate these tests.

Can patients with rectal cancer who have a near-complete clinical response to total neoadjuvant therapy be watched and potentially spared a permanent ostomy?

Neoadjuvant immunotherapy yielded similar survival and surgical outcomes to upfront surgery in high-risk HCC and could broaden surgical options for traditionally unresectable cases.

Just 0.5% of patients receiving SBRT to treat oligometastatic cancer experienced severe adverse events within 6 months, a large real-world trial found.

This approval follows recent concerns from an FDA committee that AstraZeneca did not demonstrate that patients needed the immunotherapy both before and after surgery.

A recent review suggests that incorporating patient-reported outcome measures into cancer care may improve survival and quality-of-life in the short-term but not hospitalizations.

Incyte said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.

Bayer won a legal victory in its fight to limit liability from claims that its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law...

Bayer won a legal victory in its fight to limit liability from claims its Roundup weed killer causes cancer, as a U.S. appeals court said on Thursday that federal law...

Researchers studied RNA from tumors of premenopausal women with HR-positive breast cancer.

Women with endometriosis show a higher risk for all ovarian cancer histotypes compared with those without the condition.

Patients who underwent nipple-sparing mastectomy had higher rates of positive margins and node involvement but were less likely to receive radiation therapy.

AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its blockbuster cancer drug Imfinzi a priority review for patients with limited-stage...

The first-in-class treatment for chronic graft-versus-host disease is indicated for adult and pediatric patients weighing at least 40 kg.

Physicians offer guidance about caring for patients with terminal disease

The treatment will benefit certain patients with primary advanced or recurrent endometrial cancer.

Men make up half of BRCA1/2 mutation carriers but few receive testing for the variants, and many may be unaware of their carrier status and cancer risks.

President Joe Biden will announce Tuesday he is putting $150 million in new federal funding towards developing technology to better help surgeons successfully remove...

ASCO provided guidance on the use of abemaciclib and ribociclib in the adjuvant setting for patients with stages II and III breast cancer.

Low-income women with diabetes were less likely to receive adjuvant radiotherapy and chemotherapy to treat breast cancer compared with those without diabetes.

The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris.

Although more than 40% of cancers are considered obesity-related, excess weight is often just a contributing risk factor, leaving uncertainty about the role weight plays in cancer risk.

New data from the Women's Health Initiative revealed that metabolic syndrome and obesity each have different associations with breast cancer incidence and mortality risk in postmenopausal women.

About 45,000 people are expected in Chicago for the world's largest clinical oncology meeting.

Although provincial screening programs include the most essential elements, many could improve aspects of quality, efficacy, and impact, researchers said.

Prostate cancer screening tests lack specificity in detecting higher-grade tumors, but a new urine test could help detect aggressive cancers.

The dual HER2 blockade regimen is bringing substantial clinical benefits to a population with few therapeutic options.

New data add to the body of evidence favoring the aromatase inhibitor therapy plus ovarian suppression over tamoxifen for premenopausal women with early invasive lobular carcinoma.

Vaginal estrogen therapy appears to be safe after early breast cancer in patients with HR-negative tumors and those with HR-positive tumors concurrently treated with tamoxifen, new data suggest.

A recent study discovered that breast cancer patients who took statins, medications that lower cholesterol, had notably lower mortality rates compared with those who did not use these drugs.

Exercise can help improve sexual health in women with metastatic breast cancer and should be a key component of care, researchers said.

A study found no significant differences in survival with postoperative chemoradiotherapy vs RT alone in patients who have early-stage cervical cancer without high-risk factors.

Some oncologists have called the regimen a new standard of care, while others aren't convinced that the new first-line pancreatic cancer regimen is worth the high cost.

New data presented at ESMO suggest that assisted reproductive techniques are safe for women with BRCA1/2 mutations who have been treated for breast cancer.

The drug company voluntarily requested the withdrawal of infigratinib, citing challenges enrolling patients for the required confirmatory postmarketing trials.

Emerging science suggests urine tests could offer a convenient, cost-effective way to spot hard-to-detect cancers.

ADCs are rapidly changing the treatment landscape for patients with metastatic breast cancer, with the agents demonstrating improved efficacy and manageable risks.

The number of cancer cases and deaths in Canada will increase in 2024 and beyond as rates of cancer diagnosis and cancer-related mortality will decline.

Patients with early-stage HER2+ breast cancer could soon be offered less intensive treatment based on the results of a 27-gene panel, following findings from a meta-analysis.

An infected blood scandal in Britain was no accident but the fault of doctors and a succession of governments that led to 3,000 deaths and thousands more contracting...

Early relapsing disease has again shown the limitations of immunotherapy in triple-negative breast cancer after a trial found no overall survival benefit with the drug.

Data suggest the value of performing the CDH1 test on women under age 45 years, said a researcher.

Men in their 70s and 80s report receiving prostate cancer screening, even though guidelines recommend against it.

Adding hormone treatment to radiotherapy in low-risk prostate cancer had no significant benefit, but 2 years hormone treatment was superior to 6 months in higher risk tumours.

Most men with mCRPC in the United States do not receive recommended genetic testing for relevant mutations, suggesting efforts are needed to address barriers to testing.

Continued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.

Early relapsing disease has again shown the limitations of immunotherapy in triple-negative breast cancer after a trial found no overall survival benefit with the drug.

Weight loss during preoperative chemotherapy was one factor associated with reduced odds of undergoing surgical resection for pancreatic cancer.

The overall response rate to the CAR T therapy was 95.7% in phase 2 testing.

Decisions about who can benefit from additional screening and what screening modality is most appropriate are complex.

Axillary recurrence was rare among patients who skipped standard axillary lymph node dissection after being downstaged to node-negative disease, a recent analysis found.

The high incidence of breast cancer in women younger than 40 years may warrant clinical vigilance.

Patients undergoing post-surgery radiotherapy plus chemotherapy may benefit from a hypofractionated regimen to limit toxicities, a new study suggested.

Merck said on Monday it had discontinued an experimental combination treatment testing a new type of immunotherapy in patients with a severe form of skin cancer after side...

A recent analysis found that US counties with higher rates of PSA screening had lower rates of metastatic prostate cancer and prostate cancer mortality in subsequent years.

A new survey highlighted that using the maximum tolerated dose in metastatic breast cancer leads to significant treatment-related toxicities and reducing that dose can improve quality of life.

Community oncology practices face challenges in attracting oncology fellows, highlighting the need for more fellows to ensure long-term sustainability.

New data showed that health-related social needs and financial difficulties are associated with a higher risk of mortality in cancer survivors.

A recent meta-analysis found that overall investigational drugs demonstrate modest survival benefits and greater toxicities for patients participating in cancer clinical trials.

Fewer than half of images on different government and organization websites studied showed patients with darker skin tones.

Patients with advanced cancer and their caregivers often align on goals of care, except when it comes to decisions about costs, a new survey found.

Manni Mohyuddin, MD, highlights how he treats smoldering multiple myeloma.

Although the average amount raised in European funding rounds decreased, the number of investors increased by nearly one quarter.

Expression levels of several microRNAs in plasma samples can help predict the onset of pancreatic cancer up to 5 years prior to clinical diagnosis.

Despite improvements in breast cancer screening and treatment, Black women experience higher death rates and more aggressive forms of the disease than White women.

A small trial found "a remarkable 100% of patients were still alive at 36 months" after receiving olaparib plus standard chemotherapy.

A new survey found that most US clinicians may not be following the American Cancer Society's cervical cancer screening guidelines, which are based on the most up-to-date evidence.

Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products...

Johnson & Johnson said on Wednesday it is moving forward with a $6.48 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and...

A new nomogram is intended to identify patients at high risk for endometrial cancer and prioritize them in the hysteroscopy waiting list.

The USPSTF has shifted to a stronger recommendation to start mammograms earlier, noting a need for more research on breast cancer for Black and older women and those with dense breasts.

A new study found that taking aspirin as adjuvant therapy does not improve outcomes for patients with high-risk nonmetastatic breast cancer.

A large study supports the use of stereotactic radiosurgery in patients with 15 or more brain metastases, finding improved cognitive outcomes and comparable survival to whole brain radiation.

No adverse pregnancy, foetal, or newborn outcomes found compared with other anticancer agents except for two immunotherapies given together.

Perhaps one of your patients could benefit from a clinical trial that has recently opened in prostate cancer.

European Union marketing authorization recommended for Altuvoct for hemophilia A caused by factor VIII deficiency.

The European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers.

Definitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows.

Radiotherapy decisions should be made using refined genomic guidance, as recommended by 2021 updated international guidelines, to better identify patients with molecularly aggressive disease.

CAR T-cell therapy is the best option for patients with relapsed/refractory follicular lymphoma, even though it comes with serious side effects.

Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.

The factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy.

The first-in-class agent is approved alongside bacillus Calmette-Guérin to treat certain non–muscle-invasive bladder cancers that do not respond to bacillus Calmette-Guérin alone.

A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.

Only 4% of cancer survivors reported adhering to four key healthy lifestyle practices endorsed by the American Cancer Society.

Following radical prostatectomy, however, approximately 20%-40% of patients with localized disease will experience biochemical recurrence.

A 5-year randomised, placebo-controlled trial of pembrolizumab found a 38% reduction in death vs placebo.

A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.

The approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC.

However, it's not yet clear whether a new three-phase screening intervention, which incorporates PSA test, a four-kallikrein panel, and MRI, will reduce prostate cancer mortality.

Many patients undergo lung cancer screening despite having a higher likelihood of experiencing harm rather than benefit.

The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the...

In clinical trials of cancer screening, the incidence of late-stage cancer works as well as cancer-specific mortality as an endpoint for some cancers but not others.

New data showed that Medicare reimbursement for breast cancer surgeries has declined significantly in recent years.

Colorectal cancer screening remains inadequate in France, but DNA tests could enable screening through a simple blood test or stool analysis.

ODAC unanimously backed the use of highly sensitive tests that check for minimal residual disease to speed up drug approvals for multiple myeloma.

Young breast cancer survivors with a germline pathogenic variant or who are initially diagnosed with in situ disease have more than a fourfold higher risk for a second primary breast cancer.

Researchers analyzed gut microbiota from KRAS-mutated and KRAS wild-type colorectal cancer to assess the link between disruptions in the gut microbiome and KRAS mutations in the disease.

With linvoseltamab and other bispecific antibodies inducing deep and durable responses, there might finally be a go-to option for multiple myeloma patients resistant to mainstay treatments.

Only a minority of genome-targeted cancer drugs recently approved in the United States demonstrate significant clinical benefits to patients, a new analysis found.

New treatments like bispecific antibodies and CAR T-cell therapy have helped many patients with relapsed/refractory acute lymphoblastic leukemia live longer but which is best?

Tracking a patient's circulating tumor DNA (ctDNA) can offer insight into how well-targeted therapies work in the early stages of treatment for HER2-positive cancers.

Omitting axillary surgery in patients with early breast cancer who had sentinel-node metastases and underwent surgery and radiotherapy did not compromise survival outcomes, new data show.

A survey of oncologists highlighted ethical issues over the use of AI in cancer care and revealed some contradictory views about how best to integrate these tools.

Early data suggest that several new multicancer early detection tests can identify a range of cancers that lack routine screening options.

A blood test to screen for ovarian cancer is one of many new liquid biopsy assays being evaluated to screen for cancer.

New estimates suggest that more adults with cancer are participating in cancer trial research, especially at National Cancer Institute–designated centers, but overall enrollment rates remain low.

Several new multitarget stool-based screening tests on the horizon may improve early colorectal cancer detection, according to findings from recent analyses.

Data from the ongoing phase 2 trial show that clinicians can use ImPrint, an immune-related biomarker, to identify breast cancer patients who are likely to respond to neoadjuvant immunotherapy.

A new screening test raises the possibility of catching pancreatic cancer earlier, when tumors can be removed, and patients cured.

The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.

Data suggest that intermediate clinical endpoints can serve as surrogate endpoints for overall survival in patients with early-stage breast cancer receiving adjuvant therapy.

The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.

The drug manufacturers report a complete response rate of 39% with idecabtagene vicleucel (Abecma) vs 5% with standard regimens.

A new study looks at 5-year outcomes of cancer drugs that were given accelerated approvals.

While prescription opioids are commonly used to treat moderate to severe pain in cancer patients during treatment, there is less clear guidance on using opioids after treatment ends.

Two weeks of antibiotics to eradicate the carcinogenic bacteria reduce the risk for CRC incidence and mortality, a new analysis suggested.

San Antonio–based healthcare providers have agreed to pay over $4 million in civil settlements to resolve allegations of violating the False Claims Act through an unlawful kickback arrangement.

Because this platinum drug shortage crisis won't be the last, oncology practices need to be better prepared to tackle future problems.

Omitting radiation to the lower-neck region in patients with early-stage nasopharyngeal cancer provided similar survival outcomes and reduced long-term toxicity compared to whole-neck irradiation.

Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on...

A Finnish study shows that adding polygenic risk scores to positive family histories and breast cancer-associated gene mutations improves risk stratification for breast cancer screening.

The incidence of pancreatic adenocarcinoma has been increasing steadily for more than 30 years.

A tablet has been approved for a common complication during treatment for a rare blood disorder.

Perhaps one of your patients could benefit from a clinical trial that has recently opened in prostate cancer.

Treatment decisions for patients with NSCLC metastasized to the brain should involve a multidisciplinary team, considering factors such as immunotherapy efficacy and optimal treatment sequences.

Many women with cancer want advice for managing sexual function issues, and clinicians are tuning in, new studies suggest.

A palliative Quad Shot radiotherapy regimen alongside concurrent immunotherapy can improve local control in symptomatic patients with head and neck cancer but may not improve overall survival.

Physicians should feel reassured in recommending active surveillance as a management strategy for low-risk cancers, as no successful malpractice cases related to this approach have been found.

Physicians should feel reassured in recommending active surveillance as a management strategy for low-risk cancers, as no successful malpractice cases related to this approach have been found.

A recent ASCO guideline provides recommendations for routine and additional vaccinations for adults with solid tumors or hematologic malignancies as well as their household contacts.

Minimally invasive surgery for ovarian cancer does not appear to affect survival compared with open surgery when tumors are completely removed.

Nonmetastatic microsatellite instability colorectal cancers nevertheless entailed a high risk for recurrence in stage III, especially when not treated with adjuvant chemotherapy.

Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.

Screening for lung cancer can identify more than lung malignancies.

The investigational drug led to encouraging overall survival and intracranial disease control in patients with small-cell lung cancer, longer-term trial data suggested.

Novocure's therapy met the main goal of a late-stage trial of slowing the progression of cancer to the brain in patients with a type of lung cancer, the company said on...

Novocure said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer.

New research confirms racial disparities in survival outcomes and representation in clinical trials among Black and White women with a common subtype of endometrial cancer.

Screening for lung cancer can detect other health issues and can provide information on three of the top ten causes of death.

Administering immunotherapy via subcutaneous infections could save clinicians time and money and patients may prefer it.

A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.

Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.

Mirvetuximab soravtansine-gynx (Elahere) is approved for patients with folate receptor–alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the progress of ongoing...

Cancer survivors who were older at diagnosis were more likely to follow cancer screening guidelines, whereas those who were younger were more likely to get heart tests.

The European Medicines Agency has recommended Fabhalta for treating paroxysmal nocturnal hemoglobinuria after reviewing clinical trial results.

A gastroenterologist and oncologist recently reviewed the appropriate assessment and treatment of patients with chemotherapy-associated diarrhea.

A new study pinpointed potential predictive factors for secondary myelodysplastic syndrome or acute myeloid leukemia after PARP inhibitor therapy in women with ovarian cancer.

Researchers added low-dose radiation to standard first-line treatment for extensive-stage small cell lung cancer to extend treatment benefits.

Identifying sarcopenia early in patients with oropharyngeal squamous cell carcinoma can help predict the need for feeding tube placement.

Identifying sarcopenia early in patients with oropharyngeal squamous cell carcinoma can help predict the need for feeding tube placement.

Merck said on Thursday a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung...

As CHIP is better understood, its cardiovascular and oncological risks are more clearly defined, along with what to do about them, say experts.

The model's easier-to-understand process marks an important milestone in the quest to bring AI to bedside in a meaningful way.

An FDA advisory panel endorsed earlier use of CAR-T therapies to treat multiple myeloma but emphasized the importance of informing patients about potential risks associated with these treatments.

New data from a prospective study support non-radical surgery (simple hysterectomy or cone biopsy) for early-stage low-risk cervical cancer.

Bristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a late-stage study evaluating it as an initial treatment for a type of liver...

The father of cancer immunotherapy, Steven A. Rosenberg, reflects on the patients who inspired his groundbreaking research.

An analysis of the FAERS database found the incidence of secondary cancers following CAR T therapy represented 4.3% of all adverse events; however, only 0.1% were secondary T-cell malignancies.

This is the first targeted treatment approved for upfront use in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.

ChatGPT accurately answers common questions regarding gynecologic cancers but falls short in providing treatment recommendations, two separate studies found.

Three new studies exploring treatment de-escalation of HPV-associated oropharynx squamous cell carcinoma added to data showing it's possible to reduce toxicity without jeopardizing oncologic outcomes.

Study showed that exosomes (tiny spheres released by cells) can deliver potent immunotherapy to lung cancer tumors.

The RUBY trial shows that adding an immune checkpoint inhibitor to chemotherapy improved overall survival by over 1 year for women with advanced or recurrent endometrial cancer.

Adding pembrolizumab to concurrent chemoradiotherapy does not affect quality of life in patients with high-risk locally advanced cervical cancer, new data show.

A review article surveys the literature and considers dietary supplementation to achieve optimal vitamin D levels.

After using the BCI test assay, physicians adjusted their treatment recommendations for patients with hormone receptor–positive breast cancer, according to a new study.

The accelerated approval for liso-cel was based on findings showing 20% of patients achieved a complete response from a one-time infusion after at least two prior lines of therapy.

Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an...

Researchers found that patients with locally advanced cervical cancer who received less than whole uterus irradiation had low local recurrence rates and fewer side effects.

Researchers delve deeper into metabolic syndrome trajectories finding that adults with persistent and worsening metabolic syndrome over time are at increased risk for any type of cancer.

The checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor.

There are surprisingly little data on how to safely combine new targeted treatments for breast cancer alongside radiotherapy. Experts weigh in on what we know.

Adding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.